Your email has been successfully added to our mailing list.

×
0 0 0 0.0454545454545455 0.0909090909090908 -0.0818181818181819 -0.104272727272727 -0.145454545454545
Stock impact report

Alimera’s ILUVIEN® Receives Positive NICE Recommendation for Non-Infectious Posterior Uveitis

Alimera Sciences, Inc. (ALIM) 
Last alimera sciences, inc. earnings: 4/29 04:00 pm Check Earnings Report
Company Research Source: GlobeNewswire
ATLANTA, June 20, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that the United Kingdom's National Institute for Health and Care Excellence (NICE), in its Final Appraisal Determination for national reimbursement, has recommended funding for ILUVIEN 190 micrograms intravitreal implant in applicator for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment (NIPU). “The NICE coverage decision for ILUVIEN is welcome news for patients in the U.K. suffering from this disease, as reducing relapse is a priority in the management of this condition,” said Mr. Carlos Pavesio, Specialist Uveitis Consultant Ophthalmologist at Moorfields Eye Hospital, London, U.K. “Preventing vision loss associated with relapse has a huge impact on patients’ quality of life.” In the United Kingdom, a Show less Read more
Impact Snapshot
Event Time:
ALIM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ALIM alerts
Opt-in for
ALIM alerts

from News Quantified
Opt-in for
ALIM alerts

from News Quantified